

REMARKS

Claim 7 is amended to include the limitations of claim 14 which was dependent from claim 7. Likewise, claim 15 is amended to include the limitations of claim 26 which was dependent from claim 15. As such, these amendments to claims 7 and 15 do not add new matter. Claims 14 and 26 are accordingly canceled.

Claim 19, which is a method claim, has been amended to include the limitation that the accelerator system does not contain tetramethylthiuram disulfide or diphenylguanidine. As amended, claim 19 recites the same subject matter as claim 15, except that the species of thiourea of 1,3 dibutyl thiourea is recited in the claim. Accordingly, this amendment to claim 19 is supported in the specification and does not add new matter.

At page 3 of the Office Action, the Examiner objects to claims 14 and 26 as being dependent on rejected base claims (claims 7 and 15, respectively) and indicates that the claims 14 and 26 would be allowable if rewritten to include the limitations of the base claims and any intervening claims. The applicant gratefully acknowledges this indication of allowability. Claims 7 and 15 are rewritten herein to include the limitations of claim 7 and 15, respectively, thus effectively rewriting claims 14 and 26 to include the limitations of the base claims and any intervening claims. Furthermore, claim 19 is amended to include the limitation that the accelerator system does not contain tetramethylthiuram disulfide or diphenylguanidine consistent with the scope of allowance indicated by the Examiner. Accordingly, the independent claims of the instant application

have all been amended to include the limitation of the dependent claims which the Examiner indicates recites allowable subject matter. Hence, allowance of the pending claims is earnestly solicited.

The claims are amended and canceled herein without prejudice to the applicant's right to assert the subject matter of the claims either as originally filed or as pending prior to the within amendment in a continuation or other patent application. The applicant, likewise, reserves his right to file a continuation or other application claiming priority of the instant application notwithstanding the claim amendments and remarks set forth herein.

At pages 2-3 of the Office Action, the Examiner rejects Claims 7-12, 15-18 and 20-25 under 35 U.S.C. § 103(a) as being obvious over GB 1,185,896 to Cain, et al. ("Cain") in view of U.S. Patent No. 6,828,387 to Wang et al. ("Wang"). Reconsideration and withdrawal of this rejection is respectfully requested.

As discussed above, claims 7 and 15 have been amended to incorporate the limitations of claims 14 and 26, respectively. Claims 14 and 26 were not rejected as obvious over these references and further were found by the Examiner to recite allowable subject matter. Claims 8-12, 16-18 and 20-25 are directly or indirectly dependent from claims 7 or 15. Hence, this claim rejection is now moot in the context of the instant application. Thus, no remarks by the applicant are necessary at this time, however, the applicant reserves his right to comment on the scope of this claim rejection should the same references be cited in a continuation or other application claiming priority from the instant application or otherwise.

At page 3 of the Office Action, the Examiner rejects Claims 13 and 19 under 35 U.S.C. § 103(a) as being obvious over Cain in view of Wang and further in view of JP 55-144037 to Urabe *et al.* ("Urabe"). Reconsideration and withdrawal of this rejection is respectfully requested.

Claim 13 is dependent from claim 7, however, as discussed above claim 7 had been amended to include the limitations of claim 14 that the composition does not contain tetramethylthiuram disulfide or diphenylguanidine. In the Office Action, the Examiner indicates that claim 14 recites allowable subject matter and thus the amendment to claim 7 herein places the claim in condition for allowance. Hence, this rejection with respect to claim 13 is now moot.

Claim 19 is amended to include the limitation that the accelerator system does not contain tetramethylthiuram disulfide or diphenylguanidine. Thus, claim 19 has been amended consistent with the scope of subject matter indicated allowable by the Examiner. Hence, claim 19, as amended, is not obvious over Cain in view of Wang and further in view of Urabe.

In light of the amendments to the claims consistent with the scope of allowable subject matter, the applicants have not, and need not at this time, present any further remarks with respect to the specific comments made by the Examiner in rejecting claims 13 and 19 under Cain in view of Wang and further in view of Urabe. The applicant, however, reserves his right to comment on the scope of this claim rejection should the same references be cited in a continuation or other application claiming priority from the instant application, or otherwise.


Conclusion

The instant application is believed to be in condition for allowance. A Notice of Allowance of claims 7-13 and 15-25 is respectfully requested. The Examiner is invited to telephone the undersigned at (908) 722-0700 if it is believed that further discussions, and/or additional amendment would help advance the prosecution of the instant application.

If any extension of time for this response is required, applicant requests that this be considered a petition therefor. Please charge any required petition fee to the Deposit Account No. 14-1263.

Please charge any insufficiency of fees, or credit any excess, to the Deposit Account No. 14-1263.

Respectfully submitted,



Mark A. Montana
Registration No. 44,948

November 7, 2005

NORRIS, McLAUGHLIN & MARCUS
P.O. Box 1018
Somerville, NJ 08876-1018
(908) 722-0700

101221-688 US